Literature DB >> 20180482

Provider adherence to clinical guidelines related to lipid-lowering medications.

Shannon Munro Cohen1, Merle Kataoka-Yahiro.   

Abstract

The objective of this study was to determine whether health care providers at the Department of Veterans Affairs Medical Center (VAMC) in Salem, Virginia were adherent to lipid-lowering medication guidelines over a 5-year period. Five hundred randomly chosen electronic medical records of veterans with diabetes, congestive heart failure, and/or coronary artery disease were examined for the use of HMG-CoA reductase inhibitors as part of a larger study on patient-provider adherence to cardiovascular risk-reduction guidelines. Study findings indicated that health care providers prescribed HMG-CoA reductase inhibitors to patients at high risk per evidence-based guidelines. Provider adherence to guidelines rose each year of the study, which coincided with the Department of Veterans Affairs Medical Center efforts to educate health care providers about the evidence-based guidelines, utilization of computer-generated reminders, open access appointment scheduling, and increased collaboration with patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180482     DOI: 10.7205/milmed-d-09-00062

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  3 in total

Review 1.  Predictors of statin adherence.

Authors:  Alexander Mauskop; William B Borden
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

2.  Reasons for not meeting coronary artery disease targets of care in ambulatory practice.

Authors:  Thomas Erling Kottke; Zacharia Ogwang; James C Smith
Journal:  Perm J       Date:  2010

3.  Adherence to Statin Therapy Among US Adults Between 2007 and 2014.

Authors:  Lisandro D Colantonio; Robert S Rosenson; Luqin Deng; Keri L Monda; Yuling Dai; Michael E Farkouh; Monika M Safford; Kiran Philip; Katherine E Mues; Paul Muntner
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.